Evaluation of the allelopathic potential of fifteen common Malaysian weeds

The use of allelopathy concept in weed management has received attentions to minimize extensively the reliance on herbicide applications on the agriculture industry in Malaysia. A laboratory study was conducted to evaluate the allelopathic potential of 15 Malaysian common weed species of different morphological characteristics (broadleaves, sedges and grasses). They were screened using the Sandwich method (from leaf litter leachate) and the Dish pack method (for testing the presence and content of volatile compounds in weeds). Among the 15 weed species tested, the leaf litter leachate of Centrosema pubescens was observed to be the most sensitive plant material inhibiting the growth of lettuce radicle (84%) and hypocotyl (55%) in the Sandwich bioassay compared to the control. This was followed by Asystasia gangentica (81%) and Cynodon dactylon (80%) inhibiting the lettuce radicle growth. In the Dish pack bioassay, Rhynchelytrum repens demonstrated maximum inhibition on the radicle and hypocotyl elongations by 44% and 29%, respectively, (over control) at 41 mm distance from the source well. Meanwhile, at the same distance, Cynodon dactylon was observed to have the least inhibitory effect on lettuce radicle growth by 12%. The results presented can be utilized as benchmark information for further research on the identification and isolation of allelochemicals for weed control strategies

Review of Manufacturing Process of Natural Fiber Reinforced Polymer Composites

Lately, natural fibers have been gaining consideration in development of composites due to its biodegradability, availability and low-cost compared to synthetic fibers. Natural fibers are renewable sources, biodegradable, environmentally friendly and effortless in machinery. In this paper, the manufacturing of production for natural fiber reinforced polymer composite (NFRC) will be reviewed. These including injection molding, resin transfer molding (RTM), pultrusion, sheet molding compound (SMC) and compression molding processing technique. Injection molding and compression molding are mostly used in the industry. This is due to the machines give a good finishing surface of the products and low cos

Arl3 regulates a transport system for farnesylated cargo

Arl3 is a small G-protein that is found exclusively in ciliated organisms. In addition, knocking out of Arl3 results in a plethora of ciliopathies. Arl3 is known to bind the photoreceptor (specialized cilia) specific PDE delta subunit (PDE6D), which in turn bind to prenylated proteins. The significance of this interaction and the function of Arl3 in cilia are poorly understood. Here in this study, by solving the crystal structure of a fully modified prenylated (farnesylated) Rheb in complex with PDE6D and comparing it to a structure of PDE6D in complex with the Arl3 homologue Arl2, we show that Arl3 is an allosteric regulator of PDE6D. Arl3, in a nucleotide dependent manner, releases the farnesylated cargo bound to PDE6D. We explain the molecular mechanism of this release and we further verify the mechanism in vitro and by live cell imaging. Based on this study we hypothesize that Arl3 regulate the targeting of prenylated cargo in and out the cilia

Properties-activity correlation of Nickel supported on fibrous Zeolite-Y for dry reforming of methane

Nickel-supported Fibrous zeolite-Y (Ni/FHY) was successfully synthesized via the microemulsion method using HY as seed, followed by catalytic evaluation in dry reforming of methane (DRM) for hydrogen production. Ni/FHY possessed good NiO distribution, improved metal-support interface, and strong basicity, accredited to the fibrous structure of FHY. This unique morphology led to the enrichment in the amount of accessible Ni active sites, thus resulting in the superior activity of Ni/FHY (XCH=95.1%,XCO=91.1%,H2/CO=0.89) compared to Ni/HY (XCH=92.7%,XCO=89.8%,H2/CO=0.78). Meanwhile, the inferior performance of Ni/HY could be caused by the poor distribution of Ni with large particles, thus contributing to high carbon deposition and Ni sintering. The unique physicochemical properties and superior catalytic activity confirmed its viability in the DRM

Effect of copulation on potentially precancerous prostate lesions, serum testosterone and prolactin levels in rats

The prostate is an exocrine reproductive gland that participates in ejaculation and it is prone to diseases, including cancer. Aim: In the present study, we assessed the long­term effects of copulation on the development of precancerous lesions in rats, and compared them with testosterone­induced prostatic lesions. Materials and Methods: One group of Wistar males was given 10 copulatory sessions to one ejaculation with ovariectomized, hormone­primed females. Sessions occurred twice per week for a total of ten trials. A second group was exposed to females during the same trials, but physical contact was prevented. In addition, each group received a subcutaneous implant in the back either filled with testosterone propionate (T, 100 mg/kg) or empty. This resulted in four subgroups: 1) Control + No sex, 2) Control + Sex, 3) T + No sex and 4) T + Sex. Two days after the 10th trial all the males were sacrificed for prostate histo logy (H&E) and hormone analysis (testosterone and prolactin). Results: Males from the group Control + No sex expressed normal histo logy. However, those in the groups Control + Sex and T + No sex expressed metaplasia and dysplasia in both the dorsolateral and ventral portions of the prostate, respectively. Interestingly, males from the group T + Sex expressed dysplasia in the dorsolateral prostate only, but not in the ventral prostate. Conclusions: These results indicate that constant copulation may facilitate the development of prostatic lesions in males with normal levels of testosterone. However, copulation induces less lesions in the ventral prostate of males treated with testosterone

Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes

IMPORTANCE: Patients with type 2 diabetes are at high risk of cardiovascular disease (CVD) in part owing to hypertriglyceridemia and low high-density lipoprotein cholesterol. It is unknown whether adding triglyceride-lowering treatment to statin reduces this risk. OBJECTIVE: To determine whether fenofibrate reduces CVD risk in statin-treated patients with type 2 diabetes. DESIGN, SETTING, AND PARTICIPANTS: Posttrial follow-up of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Study between July 2009 and October 2014; 5 years of follow-up were completed for a total of 9.7 years at general community and academic outpatient research clinics in the United States and Canada. Of the original 5518 ACCORD Lipid Trial participants, 4644 surviving participants were selected based on the presence of type 2 diabetes and either prevalent CVD or CVD risk factors and high-density lipoprotein levels less than 50 mg/dL (<55 mg/dL for women and African American individuals). INTERVENTIONS: Passive follow-up of study participants previously treated with fenofibrate or masked placebo. MAIN OUTCOMES AND MEASURES: Occurrence of cardiovascular outcomes including primary composite outcome of fatal and nonfatal myocardial infarction and stroke in all participants and in prespecified subgroups. RESULTS: The 4644 follow-on study participants were broadly representative of the original ACCORD study population and included significant numbers of women (n = 1445; 31%), nonwhite individuals (n = 1094; 21%), and those with preexisting cardiovascular events (n = 1620; 35%). Only 4.3% of study participants continued treatment with fenofibrate following completion of ACCORD. High-density lipoprotein and triglyceride values rapidly equalized among participants originally randomized to fenofibrate or placebo. Over a median total postrandomization follow-up of 9.7 years, the hazard ratio (HR) for the primary study outcome among participants originally randomized to fenofibrate vs placebo (HR, 0.93; 95% CI, 0.83-1.05; P = .25) was comparable with that originally observed in ACCORD (HR, 0.92; 95% CI, 0.79-1,08; P = .32). Despite these overall neutral results, we continued to find evidence that fenofibrate therapy effectively reduced CVD in study participants with dyslipidemia, defined as triglyceride levels greater than 204 mg/dL and high-density lipoprotein cholesterol levels less than 34 mg/dL (HR, 0.73; 95% CI, 0.56-0.95). CONCLUSIONS AND RELEVANCE: Extended follow-up of ACCORD-lipid trial participants confirms the original neutral effect of fenofibrate in the overall study cohort. The continued observation of heterogeneity of treatment response by baseline lipids suggests that fenofibrate therapy may reduce CVD in patients with diabetes with hypertriglyceridemia and low high-density lipoprotein cholesterol. A definitive trial of fibrate therapy in this patient population is needed to confirm these findings. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00000620